c-Myc drives uncontrolled cell proliferation in various human cancers. However, in mouse embryo fibroblasts (MEFs), c-Myc also induces apoptosis by activating the p19Arf tumor suppressor pathway. Tbx2, a transcriptional repressor of p19Arf, can collaborate with c-Myc by suppressing apoptosis. MEFs overexpressing c-Myc and Tbx2 are immortal but not transformed. We have performed an unbiased genetic screen, which identified 12 oncogenes that collaborate with c-Myc and Tbx2 to transform MEFs in vitro. One of them encodes the LPA2 receptor for the lipid growth factor lysophosphatidic acid (LPA). We find that LPA1 and LPA4, but not LPA3, can reproduce the transforming effect of LPA2. Using pharmacological inhibitors, we show that the in vitro cell transformation induced by LPA receptors is dependent on the Gi-linked ERK and PI3K signaling pathways. The transforming ability of LPA1, LPA2 and LPA4 was confirmed by tumor formation assays in vivo and correlated with prolonged ERK1/2 activation in response to LPA. Our results reveal a direct role for LPA receptor signaling in cell transformation and tumorigenesis in conjunction with c-Myc and reduced p19Arf expression.
Introduction
Almost all human cancers are the unfortunate consequence of accumulating mutations that lead to oncogene activation and tumor suppressor inactivation. These changes are ultimately subject to selection of collaborative pathways that promote proliferation, evasion from apoptosis and metastasis. The c-Myc transcriptional regulator is one of the most studied classical oncoproteins, the aberrant expression of which is implicated in many human cancers. Enhanced expression of Myc-family members is involved in nearly every feature of tumorigenesis. However, c-Myc overexpression by itself fails to induce cell transformation in primary human or rodent cells (Land et al., 1983; Drayton et al., 2003; Adhikary and Eilers, 2005) . Therefore, additional mutations are necessary for cell transformation and tumor initiation. These mutations either activate oncogenes that collaborate with c-Myc, such as Ras, and/or inactivate tumor suppressor pathways that protect cells from transformation by c-Myc, such as the p19Arf-Mdm2-p53 tumor suppressor pathway. Activated Ras cooperates with c-Myc to induce cell transformation and oncogenesis (Land et al., 1983) . On the contrary, the p19Arf tumor suppressor is one of the fail-safe mechanisms that protect cells against excessive mitogenic signals (Sherr, 2004; Gil and Peters, 2006) .
In primary mouse embryo fibroblasts (MEFs), c-Myc induces apoptosis through p19Arf upregulation and subsequent p53 pathway activation (Zindy et al., 1998) . In addition, p19Arf inhibits the function of c-Myc by direct interaction and inhibition of its transactivation ability independent from p53 (Datta et al., 2004; Qi et al., 2004; Sherr, 2006) . These actions of p19Arf antagonize c-Myc and inhibit cellular proliferation. Hence overexpression of c-Myc in p19Arf-deficient MEFs allows cells to proliferate rather than undergo apoptosis (Jacobs et al., 1999) .
In a senescence bypass screen, we identified Tbx2 as a transcriptional repressor of p19Arf (Jacobs et al., 2000; Lingbeek et al., 2002) . Tbx2 is able to downregulate p19Arf to immortalize c-Myc overexpressing MEFs, yet it is not sufficient to fully transform these cells to allow growth in soft agar. This interesting observation provided us with a base to screen for cooperative genes that enable cellular transformation, as measured by anchorage-independent growth in soft agar. To identify genes that collaborate with c-Myc and Tbx2 in tumorigenesis, we have performed a genetic gain of function transformation screen in MEFs overexpressing both genes. We identified 12 genes belonging to diverse functional groups that cooperated with c-Myc and Tbx2 to transform MEFs. One of the inserts encoded LPA2, a G protein-coupled receptor (GPCR) for the lipid mediator lysophosphatidic acid (LPA).
Lysophosphatidic acid acts on several GPCRs triggering Ras-ERK, Rho, Rac and PI3K pathway activation which in turn stimulate the proliferation, migration and survival of many cell types, both normal and malignant (Ishii et al., 2004; Moolenaar et al., 2004) . LPA signaling has been implicated in the progression of human cancers such as ovarian, prostate and colorectal cancer (Mills and Moolenaar, 2003) . Given the emerging evidence for a role of LPA signaling in cancer, we sought to examine the transforming potential of the LPA2 receptor (and its relatives) in combination with c-Myc and Tbx2 both in vitro and in vivo. We demonstrate that enhanced expression of some, but not all, LPA receptors transforms cells in combination with c-Myc and Tbx2 in vitro and in vivo. In addition, we examine the contribution of downstream LPA signaling pathways to cell transformation.
Results
Identification of genes that cooperate with c-Myc and Tbx2 in cell transformation using a genetic screen Tbx2 downregulates p19Arf levels to a specific threshold, just enough to immortalize MEFs and counteract c-Myc-induced apoptosis (Jacobs et al., 2000) . The residual p19Arf level is however still capable of suppressing transformation. Therefore, MEFs coexpressing c-Myc and Tbx2 are immortal, but not transformed (Supplementary Figure 1) . We have taken advantage of this cooperation to design an unbiased transformation screen to find genes that will transform MEFs in combination with c-Myc and Tbx2, using retroviral cDNA expression libraries (Jacobs et al., 2000) . This genetic predisposition allows the appropriate stringency, as c-Myc overexpressing p19Arf-deficient MEFs transform more easily, regardless of the introduced cDNA, and cause high background (Supplementary Figure 1) .
Early passage primary MEFs were transduced with retroviruses containing Tbx2 and c-Myc (hereafter called c-Myc/Tbx2-MEFs) and subsequently transduced with retroviral cDNA libraries derived from different human tumors and normal tissues (Jacobs et al., 2000) . Infected c-Myc/Tbx2-MEFs were then plated in soft agar and screened for colony formation (Figure 1 ). Colonies were picked and expanded as monolayers. The colonies differed in adhesion properties, ranging from semiadherent to almost nonadherent floating spheres. As expected, we observed no background colonies in c-Myc/Tbx2 cells that were transduced with retroviruses containing no insert (negative control).
Using long range PCR and sequencing analysis, 12 cDNA inserts were identified, subcloned and reintroduced in c-Myc/Tbx2-MEFs to verify their transforming ability. Most inserts contained a full-length cDNA and belonged to different functional groups (Table 1) .
The first group contained the cytoskeletal proteins a-actinin-4 (Actn4), filamin C (FlnC) and laminin-binding protein 32 (Lbp-32). We also found truncated Dbs, constitutively active mutant of a Rho-specific guanine nucleotide exchange factor, which is involved in cytoskeletal remodeling and cell cycle progression (Kostenko et al., 2005) . The second group contained components of the Ras-Raf-ERK signaling pathway (Raf-1, Map3k3 and FosB) that is known to cooperate with c-Myc in cell transformation. The third group contained PdgfB and Hrs, both involved in receptor tyrosine kinase signaling (Benito and Lorenzo, 1993; Toyoshima et al., 2007) . Among the remaining genes, we identified Nek6, a serine/threonine kinase implicated in mitotic G2-M progression (O'regan et al., 2007) and Agrn, a large proteoglycan involved in neuromuscular junction development (Bowe and Fallon, 1995) . This last group also contained LPA2, a GPCR for LPA.
As mentioned, Tbx2 reduces p19Arf levels but does not completely abolish it. As the p19Arf threshold levels have a decisive function in transformation, we examined the transforming ability of the identified genes in the complete absence of p19Arf and in combination with c-Myc (Figure 2 Figure 1 Schematic outline of the in vitro genetic transformation screen: mouse embryo fibroblasts (MEFs) were transduced with retroviruses containing Tbx2 and c-Myc, respectively at passages 1 and 2. Thereafter, they were transduced with human retroviral cDNA libraries and subsequently were plated in soft agar, allowing selection for anchorage-independent growth. Colonies were picked after 2-3 weeks and expanded for further analysis. To enrich for the relevant insert a secondary screen was performed. Southern blot, PCR and sequence analysis were used to indentify the inserts. These results reveal novel and established cooperative pathways for c-Myc and Tbx2 in transformation and underline the strength of gain-of-function screens to identify new oncogenes and oncogenic cooperations.
Transforming potential of LPA receptors in vitro and in vivo Lysophosphatidic acid acts on at least five distinct GPCRs (LPA1-5), which show both overlapping and distinct signaling properties and tissue expression (Ishii et al., 2004; Moolenaar et al., 2004) . The so-called 'Edgfamily' LPA receptors (LPA1, LPA2 and LPA3) are the best studied, whereas LPA4 and LPA5 receptors have Twelve genes belonging to distinct functional groups (cytoskeletal remodeling, Ras-Raf-ERK pathway, RTK signaling, lipid signaling, extracellular matrix and G2-M cell cycle progression) listed here, were identified and verified to transform mouse embryo fibroblasts in combination with c-Myc and Tbx2 (reduced p19Arf levels). Five of the identified inserts contained 5'truncated cDNA's. only recently been identified and are more closely relayed to the purinergic receptor family (Noguchi et al., 2003; Lee et al., 2006a) . Growing evidence points to a function of LPA receptor signaling in tumor progression and metastasis (Mills and Moolenaar, 2003) . LPA1 overexpression in breast carcinoma cells drives their metastatic spread to bone (Boucharaba et al., 2004) , while the LPA-producing exoenzyme autotaxin is found overexpressed in various cancers and promotes tumor progression in preclinical models (van Meeteren and Moolenaar, 2007) . However, the function of LPA receptor signaling during the initiating steps of tumor formation has not been investigated so far.
Having found that LPA2 can transform Myc/Tbx2-MEFs, we next examined if three other GPCRs for LPA, namely LPA1, LPA3 and LPA4, share this ability. Myc/Tbx2-MEFs were transduced with retroviruses encoding LPA1-4, RasV12 or with control vector and examined for growth in soft agar. As expected, RasV12-expressing Myc/Tbx2-MEFs transformed easily ( Figure 3 ). Both LPA1 and LPA4 reproduced the transforming capacity of LPA2 (Figures 3b and c) . Strikingly, LPA3 failed to induce a transformed phenotype in Myc/Tbx2-MEFs even though LPA3 expression levels were significantly higher than those of the other LPA receptors (Figure 3a and Supplementary Figure 2 ). If overexpression of LPA receptors can transform Myc/Tbx2-MEFs, would overstimulation of endogenous LPA receptors by LPA be sufficient to trigger the same effect? To address this question, we plated Myc/Tbx2-MEFs in soft agar in the presence or absence of 5 or 10 mM LPA. Figure 3d shows that addition of excess LPA (up to 10 mM) does not induce transformation of Myc/Tbx2-MEFs. This is consistent with the amount of LPA in serum-containing medium being saturating, and it suggests that the number of endogenous LPA receptors and, hence, signal strength determines the extent of transformation.
In addition, we analysed how p19Arf may affect LPA receptor-mediated transformation. We therefore compared c-Myc/Tbx2-MEFs with p19Arf-deficient c-Myc-MEFs expressing LPA1-4 (Figure 3e) . Similar to what is observed with LPA2 (Figure 2 ), the absence of p19Arf strongly potentiated the LPA1-and LPA4-induced transformation (Figure 3e ). Again, LPA3 was incapable of transforming MEFs even in the absence of p19Arf. None of the LPA receptors tested could induce transformation in combination with either Tbx2 or c-Myc alone (data not shown), consistent with c-Myc and Tbx2 being cooperating partners in cell transformation. These results indicate a direct role for LPA receptor signaling in oncogenic transformation in cooperation with c-Myc and Tbx2. Furthermore, they reveal that LPA3 mitogenic signaling differs fundamentally from that induced by LPA1, LPA2 and LPA4.
We next examined the ability of LPA receptors to induce tumor formation in vivo. To this end, 10 6 Myc/ Tbx2-MEFs overexpressing distinct LPA receptors, RasV12 or control vector were subcutaneously injected into nude mice, and tumor formation was monitored up to 75 days. As shown in Figure 4 , control c-Myc/Tbx2-MEFs failed to form tumors, whereas RasV12 MEFs produced sizeable tumors within 10 days. Overexpression of LPA1, LPA2 or LPA4 in Myc/Tbx2-MEFs induced tumor formation very efficiently. In contrast, LPA3 overexpression did not lead to detectable tumor formation over a 3-month period. These results are fully consistent with the in vitro (soft agar) data and show that overexpression of LPA1, LPA2 or LPA4 is sufficient to initiate tumor formation in combination with c-Myc and Tbx2.
LPA receptor-induced transformation depends on Gi, ERK and PI3K activity Which LPA signaling pathways are responsible for mediating cell transformation? LPA receptors couple to multiple G-proteins, particularly Gi/o, Gq/11 and G12/ 13, to activate various downstream effectors. LPAinduced cell proliferation and survival are critically dependent on the Gi-linked Ras-MAP kinase and PI3K pathways (Moolenaar et al., 2004) . We tested the effect of pertussis toxin (PTX), which specifically ADPribosylates Gi/o proteins and thereby prevents their activation. PTX treatment (50 ng/ml) completely abolished cell transformation induced by LPA1, LPA2 and LPA4 in c-Myc/Tbx2-MEFs, but not the transformation induced by RasV12 (Figure 5a ). Thus, Gi signaling is essential for LPA receptors to transform MEFs. Figure 5a also shows that PD-98059 (10 mM), a specific inhibitor of ERK1/2, strongly inhibited LPA receptorinduced transformation of Myc/Tbx2-MEFs. In addition, we examined the involvement of the PI3K pathway using the PI3K inhibitor LY-294002 and its inactive analog LY-303511. As shown in Figure 5b , transformation of Myc/Tbx2-MEFs expressing distinct LPA receptors is severely inhibited by LY-294002 (5 mM), whereas LY-303511 (up to 10 mM) had no effect. From these results, we conclude that LPA receptor-induced transformation is dependent on both the Gi-linked ERK1/2 and PI3K pathways.
RasV12-transduced cells showed only a partially reduced transforming capacity (reduced number of soft agar colonies) in the presence of ERK or PI3K inhibitors (Figures 5a and b) . Although concentrations used in these experiments may not be sufficient to inhibit RasV12-induced transformation more efficiently, it should be emphasized that Ras-induced transformation does not solely depend on either ERK1/2 or PI3K activation (Rodriguez-Viciana et al., 1994; Khosravi-Far et al., 1996; Shields et al., 2000; Zuber et al., 2000) .
Different kinetics of ERK activation by distinct LPA receptors
The ERK activation by growth factors usually shows biphasic kinetics. An initial, very transient phase of ERK activation (lasting 5-20 min.) is followed by a second phase of activation that is much more sustained. The latter phase is necessary for S-phase entry and cell proliferation (Jones and Kazlauskas, 2001) . We examined the kinetics of ERK activation in Myc/ Tbx2-MEFs expressing the respective LPA receptors.
Myc/Tbx2-MEFs overexpressing LPA1-4 receptors showed very low basal ERK1/2 activity, similar to control MEFs (Figure 6a ). Upon LPA stimulation for 5 min, all cells showed enhanced ERK1/2 activity (Figure 6a ). The LPA1-4 overexpressing cells initiated rapid MAP kinase activation similar to control cells. We then monitored the prolonged phase of LPA-induced ERK1/2 phosphorylation in LPA2-expressing MEFs versus control MEFs (Supplementary Figure 3) . The LPA2 overexpressing cells showed stronger and more sustained ERK1/2 activation (up to 2 h), when compared to control MEFs. Next, we tested ERK1/2 activation for the other three LPA receptors. Figure 6b shows that LPA1 and LPA4, similar to LPA2, maintained prolonged ERK activation (up to 2 h after LPA stimulation). In marked contrast, LPA3-overexpressing cells showed only the early transient MAP kinase activity phase but not the second prolonged phase, similar to what was observed for the control cells. In conclusion, the transforming ability of LPA receptors is closely linked with their ability to sustain prolonged ERK1/2 activation.
Discussion
In this study, we have explored pathways that cooperate with c-Myc in tumorigenesis in the context of reduced p19Arf expression. Anchorage-independent growth is one of the hallmarks of transformation and correlates with tumorigenicity in vivo. Therefore, we screened for genes and ultimately pathways that cooperate with c-Myc in transformation, using selection for anchorageindependent growth in soft agar as read-out. With this, we not only confirmed already established cooperative pathways for c-Myc in transformation, but also identified new oncogenic collaborators, underlining the use of gain-of-function screens.
In response to prolonged mitogenic signals from the c-Myc onco-protein, primary MEFs upregulate p19Arf levels and consequently undergo apoptosis (Zindy et al., 1998) . In contrast, primary cells lacking functional p19Arf efficiently bypass apoptosis and occasionally transform under high selection pressure in soft agar (Jacobs et al., 1999) . Therefore, using c-Myc overexpressing wild-type or p19Arf-deficient MEFs does not offer the proper stringency to screen for oncogenic collaborations. However, downmodulating p19Arf by Tbx2 to a threshold level that bypasses apoptosis and yet not easily predisposes cells for transformation allowed us the opportunity to screen for cooperating genes (Supplementary Figure 1 ). In addition to p19Arf, Tbx2 represses p21, which is also repressed by c-Myc (Seoane et al., 2002; Prince et al., 2004) . As c-Myc/Tbx2 overexpression in p19Arf-deficient MEFs does not cause more soft agar colonies than c-Myc overexpression alone in p19Arf-deficient MEFs (Supplementary Figure 1) , we can conclude that the main function of Tbx2 in these MEFs is to repress p19Arf.
With this screen, we identified 12 genes that induce transformation in MEFs in cooperation with c-Myc and Tbx2 (reduced p19Arf expression). It is known that c-Myc can cooperate with activated Ras and oncogenes that function in the Ras pathway to induce transformation (Land et al., 1983 (Land et al., , 1986 Drayton et al., 2003) . Corroborating this, we find truncated Raf-1, which has been shown to be the constitutively activated form of Raf-1 (Heidecker et al., 1990) . In addition, we find Map3k3 and Fosb, which are also players in the Ras-Raf-ERK pathway. Identification of genes that are already known to directly cooperate with c-Myc validates our screen.
More upstream we found the proto-oncogene PdgfB, which stimulates cellular proliferation and motility through its receptor tyrosine kinases and we identified Hrs, which is an important downstream regulator of receptor tyrosine kinase signaling. Both genes have been implicated in tumorigenesis (Pietras et al., 2003; Toyoshima et al., 2007) . Receptor tyrosine kinase signaling can activate the Ras and PI3K pathways (Ramjaun and Downward, 2007) , thereby explaining their collaboration with c-Myc and Tbx2 in transformation.
However, we also find genes that are involved in cytoskeletal remodeling, such as Actn4, truncated Dbs, FlnC and Grhl1. Regulation of cytoskeletal changes have a crucial function in cell motility, anchorageindependent growth and metastasis. For example Actn4, an actinin-bundling protein, has been implicated in breast cancer, and progressed stages of esophageal squamous cell carcinoma and lung cancer (Honda et al., 1998 (Honda et al., , 2005 Fu et al., 2007) . Moreover, recently Actn4 was found to be one of the binding partners of Akt1, thereby having a crucial function in activation and translocation of Akt1 to the cell membrane (Ding et al., 2006) . Interestingly, we find Actn4, Agrn, Dbs, FlnC, FosB, Hrs and PdgfB capable of cooperating with c-Myc alone independent from p19Arf. This transforming ability is as efficient as the transforming ability of c-Myc and RasV12. These genes may be important players up-or downstream of the Ras-Raf-ERK pathway, contributing to oncogenic transformation. They might also directly or indirectly suppress the p19Arf/p53 pathway.
p19Arf-deficient c-Myc-MEFs overexpressing Map3k3 are less transformed than c-Myc/Tbx2-MEFs overexpressing Map3k3. This observation is rather surprising, since p19Arf deficiency was expected to facilitate a stronger transformation as was observed for the other identified genes. This however suggests that other tumor suppressors (such as p16Ink4a or p15Ink4b) could be activated in p19Arf-deficient cells overexpressing the specific combination of c-Myc and Map3k3 (Krimpenfort et al., 2007) . It is also possible that Tbx2 exerts additional functions, which cooperate with Map3k3 in wild-type MEFs. Furthermore, in addition to truncated Raf-1 and Dbs, which are known to be the constitutively active mutants, we also found Agrn, FlnC and Hrs inserts to be 5 0 -truncated. Therefore, we cannot exclude any dominant negative or dominant active functions of these latter mutants.
LPA2 is one of the novel cDNA inserts that cooperates with c-Myc and Tbx2 in our screen. We show that LPA1 and LPA4, but not LPA3, can mimic the transforming action of LPA2 in c-Myc/Tbx2-MEFs in vitro and in vivo. This transforming ability is dependent on Gi, ERK and PI3K activity (Figure 6c ). Strikingly, MEFs overexpressing LPA1, LPA2 and LPA4 retain prolonged ERK1/2 activation when stimulated with LPA, whereas LPA3 is incapable of sustaining ERK1/2 activation, which may provide a mechanistic explanation for LPA3 lacking transforming potential. This suggests that sustained ERK1/2 activation may underlie the cooperation with c-Myc and Tbx2 in transformation, in particular because activated Ras can cooperate with c-Myc in tumorigenesis. Here, we show not only a direct function for LPA1, LPA2 and LPA4 in transformation, but also a vital difference amongst LPA receptors regarding their signaling and contribution to transformation and tumorigenesis.
It should be noted that overexpression of LPA receptors in MEFs by itself does not lead to 'spontaneous' receptor activation, as inferred from MAP kinase activity assays. Instead, LPA present in serum is necessary to activate LPA receptor signaling.
Overexpression of LPA2 has been implicated in ovarian cancer (Erickson et al., 2001; Lee et al., 2006b) . Even though LPA2 transgenic mice do not develop ovarian malignancies, there is a significant increase in the expression of angiogenesis and metastasis inducing factors such as VEGF, VEGF receptor and uPA in the ovaries of these mice (Huang et al., 2004) . Therefore, LPA signaling is suggested to contribute to tumor progression and metastasis rather than to promote tumor formation by itself. Here, we demonstrate that additional alterations such as enhanced c-Myc activity and inactivation of the p19Arf tumor suppressor (both frequently found in tumors) can nevertheless cooperate with enhanced LPA signaling and lead to tumor initiation. LPA receptors are not able to induce transformation in combination with c-Myc alone. The specific requirement of p19Arf repression (brought by Tbx2) for LPA receptor-induced transformation suggests that prolonged LPA signaling might trigger a p19Arf tumor suppressor response by itself.
Besides the differences in sustained MAP kinase activation downstream of LPA receptors, there may also be additional explanations underlying their distinct transforming potential. Deregulated expression of Edgfamily LPA receptors in different combinations has been reported in several cancers. Whereas enhanced expression of LPA2 has been implicated in ovarian, prostate and colon cancer, LPA1 and LPA3 expression patterns are more diverse. LPA1 and LPA2 share many downstream signaling pathways, whereas LPA3 seems to act differently. Previous analysis of LPA receptor signaling (Ishii et al., 2000) suggested that LPA3 fails to couple to the G12/13-linked RhoA pathway. RhoA not only regulates the actin cytoskeleton, but also can contribute to cell cycle progression and cell transformation (Jaffe and Hall, 2005) . To what extent G12/13-Rho signaling pathways contribute to LPA-induced cell transformation remains a challenge for future studies.
Consistent with the divergence of downstream signaling pathways of LPA1 and LPA2 versus LPA3, targeted deletion studies of LPA receptors in mice have revealed functional redundant roles for LPA1 and LPA2 in neuronal and craniofacial development (Ishii et al., 2004) , whereas LPA3 deletion leads to impaired female reproduction (Ye et al., 2005) .
Downstream signaling pathways of LPA4 have not yet been delineated as extensive as those of the Edgfamily members. LPA4 mediates calcium signaling and Rho activation through stimulation of Gq/Gi and G12/ 13, respectively, and in contrast to LPA1-3, LPA4 can raise cAMP levels by coupling to Gs (Lee et al., 2007) . Here, we report that LPA4 induces PI3K and prolonged ERK1/2 activity through Gi signaling, and we demonstrate a role for LPA4 (a non-Edg LPA receptor) in cell transformation and tumorigenesis.
Our data connect LPA1, LPA2 and LPA4 overexpression to transformation and tumorigenesis with no apparent role for LPA3 in transformation, which correlates with their capability to sustain MAP kinase activation. Although the exact mechanism by which LPA signaling promotes tumorigenesis needs to be elucidated, our study shows that LPA receptor signaling contributes not only to tumor progression, but also to tumor initiation. As the LPA receptor family is still expanding (Pasternack et al., 2008) , it remains interesting to examine the importance of those newly identified LPA receptors in tumor formation.
Materials and methods
Cell culture, constructs, retroviral production and transduction Wild-type and p19Arf-deficient MEFs were isolated and cultured as previously described (Jacobs et al., 1999) . Ecotropic retroviruses were produced by transient transfection of phoenix-packaging cells with retroviral expression vectors, using calcium-phosphate coprecipitation method. Supernatant collection started 48 h after transfection. Retroviral transduction was performed as described before (Jacobs et al., 1999) . c-Myc/Tbx2-MEFs were generated as follows: primary MEFs were transduced with retroviruses containing LZRS-Tbx2-iresGFP (Jacobs et al., 2000) at passage 1, and subsequently were transduced with retroviruses containing LZRS-MycHAiresGFP (Jacobs et al., 1999) at passage 2. For LPA receptor overexpression experiments we made use of the following human constructs: LZRS-HA-LPA1-iresNeo, LZRS-HA-LPA2-iresNeo, LZRS-HA-LPA3-iresNeo and LZRS-HA-LPA4-iresNeo. LZRS-iresNeo empty vector is used as negative control and pBabePuro-RasV12 is used as positive control. 48 h after transduction, cells were selected using 1 mg/ml G418 (Invitrogen, Carlsbad, CA, USA) or 4 mg/ml puromycin (Sigma-Aldrich, Zwijndrecht, NL, USA). The proper membrane localization of LPA receptors using the overexpression constructs has been verified by anti-HA immunofluorescence experiments (data not shown).
Soft agar assays Cells (6 Â 10 4 ) were per well of a six-well plate resuspended in Dulbecco's modified Eagle's medium (Gibco-Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (PAA laboratories, Pasching, Austria) and 0.35% low gelling temperature agarose (Sigma) and plated on top of a coating bottom-agar (Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, containing 0.6% agarose). Cells were then allowed to grow under standard conditions for 2-3 weeks, after which plates were scanned (Epson perfection 4900 photo scanner) and the amount of colonies were quantified using ImagePro-Plus 5.1 software (Media Cybernetics). All the experiments were performed in triplicate in several independently isolated batches of MEFs.
Genetic transformation screen
Retroviral cDNA expression libraries used here are: human prostate, human leukocyte, human mammary gland (Clontech, Mountain View, CA, USA), JEG3(1-3), JEG3(>3) size fractionated human JEG3 choriocarcinoma-derived cDNA library, K562(1-3) and K562(>3) size-fractionated K562 human erythroleukemia cDNA library (Jacobs et al., 2000; Koh et al., 2002) . High titer viral supernatants from libraries were freshly collected with 12 h intervals and directly used to transduce c-Myc/Tbx2-MEFs in two consecutive rounds of transduction of 1-2 Â 10 6 cells plated per 10 cm culture dishes. Empty pMXsubF-and pLIB-vectors are used as the negative control. 48 h after library transduction, cells were plated in soft agar in 10 cm culture dishes as described above. c-Myc/Tbx2-MEFs transduced with retroviruses containing RasV12 were used as positive control. After 2-3 weeks, from cells that were transduced with cDNA libraries, 175 colonies were picked and expanded as monolayers for genomic DNA isolation and secondary screen. Southern blot analysis revealed multiple integrations (1-8) per colony. To facilitate cloning and testing of the relevant inserts, a secondary screen using wild-type replication competent MoMuLV was performed as described before (Jacobs et al., 2000) . For each primary colony, 3-5 secondary colonies were picked. From 175 original colonies, 164 were positive after the secondary screen. Hereby, true positive colonies were selected for further analysis. Using longrange PCR techniques (Expand long template PCR system, Roche, Indianapolis, IN, USA) and retroviral specific primers, the transforming inserts were amplified and subsequently subcloned (TOPO TA cloning, Invitrogen) and finally identified by sequencing. Identified inserts were either cloned back into the original constructs (pLIB and pMX) or in pBabePuro and were retested in c-Myc/Tbx2-MEFs in soft agar.
Quantitative RT-PCR expression analysis Total RNA isolation was performed using TRIZOL reagent (Invitrogen). First-strand cDNA was prepared using Superscript II reverse transcriptase and oligo(dT) primers (Invitrogen). Quantitative reverse transcription-PCR is performed using an ABI PRISM 7000 Real Time PCR system and SYBR green PCR master mix (Applied Biosystems, Foster City, CA, USA). Primer sequences are: LPA1-F 5 0 -AATCGGGA TACCATGATGAGTCTT-3 0 , LPA1-R 5 0 -CCAGGAGTCCA GCAGATGATAAA-3 0 , LPA2-F 5 0 -CGCTCAGCCTGGTC AAGACT-3 0 , LPA2-R 5 0 -TTGCAGGACTCACAGCCTAA AC-3 0 , LPA3-F 5 0 -AGGACACCCATGAAGCTAATGAA-3 0 , LPA3-R 5 0 -GCCGTCGAGGAGCAGAAC-3 0 , LPA4-F 5 0 -CC TAGTCCTCAGTGGCGGTATT-3 0 , LPA4-R 5 0 -CCTTCAA AGCAGGTGGTGGTT-3 0 . The amount of target mRNA was calculated using a standard curve based on serial dilutions with known quantities (absolute quantification protocol, Applied Biosystems), and normalized to glyceraldehyde-3-phosphate dehydrogenase.
Pharmacological inhibition experiments c-Myc/Tbx2-MEFs were retroviraly transduced with LZRS-HA-LPA1-4-iresNeo, pBabePuro-RasV12 or LZRS-iresNeo empty vector. Cells were selected with 1 mg/ml G418 or 4 mg/ ml puromycin starting 48 h after transduction. Hereafter cells were plated in the presence or absence of inhibitors, namely 50 ng/ml PTX (List Biological Laboratories, Epsom, UK), 5 and 10 mM LY-294002/inactive control LY-303511 (Calbiochem, Gibbstown, NJ, USA) and 10 mM PD-98059 (Calbiochem) in soft agar as mentioned above.
ERK phosphorylation western blot analysis c-Myc/Tbx2-MEFs were retroviraly transduced with LZRS-HA-LPA1-4-iresNeo, pBabePuro-RasV12 or LZRS-iresNeo empty vector. After selection 3 Â 10 5 cells were plated per well of a six-well plate. Next day, the cells were washed with phosphate-buffered saline and grown in Dulbecco's modified Eagle's medium containing 0.1% fetal bovine serum for at least 16 h. Thereafter, cells were stimulated with Dulbecco's modified Eagle's medium containing 1 mM LPA (Avanti Polar Lipids Inc.
Alabaster, AL, USA) for indicated time points (5, 10, 30, 60, 120 or 240 min). Cells were lysed using RIPA buffer (150 mM NaCl, 1% NP40, 50 mM Tris-HCl (pH 8.0), 2 mM EDTA (pH 8.0), 0.5% DOC, 0.1% SDS) supplemented with 1 mM dithiothreitol, 1 mM phenyl-methyl-sulphonyl-fluoride, 1 mM NaVO3, 10 mM NaF, 10 mM pyrophosphate and 50 mM b-glycerophosphate). Protein expression was analysed using a conventional westernblot protocol. Primary antibodies were: monoclonal antiphospho MAP kinase antibody (Sigma 1:1000), anti-tubulin (Sigma), polyclonal anti-CDK4 (Santa Cruz 1:1000). Secondary antibodies were: goat anti mouse (Zymed, San Francisco, CA, USA) or goat anti rabbit (Biosource-Invitrogen, Carlsbad, CA, USA) both conjugated to horseradish peroxidase.
In vivo tumor formation assays Male BALB/c nude mice (7-8 weeks of age) were injected subcutaneously with 1 Â 10 6 cells (resuspended in phosphatebuffered saline) in each flank. For each condition a total of eight flanks (four mice) were injected. Tumor size was monitored every 2-3 days by measuring the length (L) and the width (W) of the developing tumor using a caliper. Tumor volume was calculated following the formula (W 2 Â L)/2. Mice were killed when tumors reached a maximum size of 1 cm in the largest diameter.
